The role of ascorbic acid in the expression of miRNA and mood in patients with depression: A randomized controlled trial.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12624000525583

Enrollment

102

Registered

2024-04-27

Start date

2021-02-23

Completion date

2021-07-29

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The initiative of the current research is to assess the effectiveness of ascorbic acid on expression levels of miRNA-132, miRNA-182, miRNA let-7b, let-7c and miRNA-124 in the treatment of depression. The present study will also measure the effect of ascorbic acid on Hamilton Depression Rating Scale (HAM-D) in patients with depression taking antidepressants.

Interventions

• In this randomized controlled trial, there will be two groups of patients suffering from depression. o Among these two groups one will be interventional group and one group will be the control group Interventional Group will be on antidepressants (conventional treatment and Ascorbic Acid 500mg orally daily once a day for three months

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used) (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

Patients with a total count of 16 or more on Hamilton Depression Rating Scale (HAM-D) both men and women with an age limit between 18years to 45 years

Exclusion criteria

Patients with sufficiently important concurrent psychiatric illness, epilepsy, bipolar affective disease, ongoing substance abuse other than cigarette smoking, suicidal attempts, pregnancy or breastfeeding.

Outcome results